lung screening News
-
It’s World Lung Cancer Day
August 1 marks World Lung Cancer Day -- a time to raise awareness of the need for increased lung cancer research and innovation. Anyone can get lung cancer. Here are the facts you need to know: Lung cancer is the leading cause of cancer deaths worldwide More patients die every year from lung cancer than from prostate, breast, and colon cancer combined The lung cancer five-year survival rate ...
-
Insights from the American Lung Association’s 2021 State of Lung Cancer Report
The American Lung Association recently released its 2021 State of Lung Cancer report. Lung cancer is the leading cause of cancer deaths worldwide because the disease is often diagnosed at the late stages. Early diagnosis of lung nodules can help patients get treatment sooner and improve long-term survival rates. Auris is committed to fighting this deadly disease by helping physicians diagnose ...
-
Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch
Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for ...
-
Biomark Announces Closing of $1,5 Million Financing Round to Accelerate Commercialization of Its Liquid Biopsy Technology
BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed a financing round to accelerate the commercialization of its liquid biopsy technology. The financing round included a non-brokered private ...
-
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
Prospective registrational study expected to enroll nearly 10,000 patients in 36 months REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate ...
-
Cancer Genomic Screening Program LC-SCRUM-Asia Adopts Latest Thermo Fisher Scientific NGS Solutions
LC-SCRUM-Asia, a leading cancer genomic screening program, has selected Thermo Fisher Scientific's Ion Torrent Genexus System* and Oncomine Precision Assay*, a pan-cancer panel, to advance precision medicine in Asia. The next-generation sequencing (NGS) solutions will be used in two prospective, observational projects to support the development of future therapeutics and diagnostics for non-small ...
-
Biomark to present validation data of its multianalyte metabolite panel for lung cancer screening at the esmo congress 2022
Vancouver, British Columbia – (September 8, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it’s abstract titled “Metabolomic Profiling for the Early Detection of Lung Cancer” has been ...
-
Biomark provides business update and second quarter financial results
Vancouver, British Columbia – (November 28, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the “Warrants”) issued in relation to ...
-
Restech will be present at the next screening day organized by the Italian League against Tumor (LILT)
Saturday 23rd of September 2017 RESTECH will participate with 2 RESMON PRO FULL devices to the “Spirometry day” organized by the Italian League against Tumor (LILT) in Bolzano. Anyone interested in having a free screening of his/her lung function can come and visit us at Piazza della Mostra from 9:00 until ...
By Restech Srl
-
AlveoliX and EpiEndo Receive Eurostar Grant
The Swiss National Science Foundation SNSF and the Swiss Innovation Agency Innosuisse have granted a BRIDGE Discovery project to the Laboratory of Microbiology at the University of Neuchâtel (LAMUN) in cooperation with the Centre Hospitalier Universitaire Vaudois (CHUV), the Swiss Institute of Bioinformatics (SIB), and two innovative Swiss startups AlveoliX AG and SiMPLInext SA. The aim of ...
By AlveoliX AG
-
AlveoliX part of a new BRIDGE Discovery project
We are thrilled to be part of the new BRIDGE Discovery project granted by the SNSF Swiss National Science Foundation and Innosuisse to the Laboratory of Microbiology at the Université de Neuchâtel (LAMUN) in cooperation with the CHUV / Centre hospitalier universitaire vaudois, the SIB Swiss Institute of Bioinformatics, ...
By AlveoliX AG
-
Prof. Krestin Joins Fluidda’S Board of Directors
INTRODUCTION Gabriel Krestin received his MD from the University of Cologne, Germany where he also specialized in radiology, in 1981 and his PhD (Habilitation) in 1989. From 1990–1997, he worked at the University Hospital in Zürich/CH, including a period as acting chairman of the Department of Radiology. In 1997 he moved to Erasmus MC in Rotterdam, Netherlands where he was the ...
By Fluidda
-
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
Highly sensitive Shield test offers convenient screening method that can be completed with simple blood draw, helping overcome barriers to compliance Test demonstrated sensitivity of 91% in colorectal cancer and 20% in advanced adenoma detection with specificity of 92% in validation studies PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you